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Abstract
Background: A physiologic test for estimating BPD rate has been developed by Walsh and collaborators. Actually
there are not standard criteria for weaning from CPAP and/or oxygen therapy the premature babies. Aim of this
study was to verify if a physiologic test, modified respect to that developed by Walsh and collaborators for
estimating BPD rate, can be used as a clinical tool for weaning the premature babies from CPAP and/or oxygen
therapy.
Methods: Neonates with BW 500–1250 g and GA ≤ 32 weeks, receiving FiO2≤ 0.30 by hood or CPAP, were
prospectively studied at 28 days of life and at 36 weeks of postmestrual age. The test was performed in 3 steps:
baseline, challenge (FiO2 and CPAP reduction to room air) and post test (room air). Monitoring of transcutaneous
CO2 was added to SpO2 and the newborns passing the test were left in room air.
Results: Six of 23 tested babies (26%) passed the challenge at 28 days of life, 4 of 10 tested babies (40%) passed
the challenge at 36 weeks. Median values of SpO2 were significantly higher in the neonates passing the test,
respect to the failing patients. At the same time median values of TcPCO2 were significantly higher in the latter
babies.
Conclusion: TcPCO2 monitoring appeared to be a new useful parameter for failure prediction of weaning. The test
represented a clinical guide because the newborns passing it were left in room air.
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Introduction
A reliable assessment of the premature infant’s ability to
maintain adequate, independent ventilation in room air is
likely to depend on an understanding of the complex inter-
action of respiratory system compliance, airway resistance,
central inspiratory drive, chest wall stability and diaphrag-
matic endurance. In our previous study we showed in the
babies successfully extubated significantly higher values of
spontaneous expiratory minute ventilation and of
respiratory rate with significantly lower transcutaneous par-
tial pressure of CO2 (TcPCO2) values during a 2 h endo-
tracheal tube continuous positive airways pressure (CPAP)
trial, respect to the babies who failed extubation attempt
[1]. On the basis of this experience, we decided to perform
a new study to verify if a physiologic test, modified respect
to that developed by Walsh and colleagues [2] for estimat-
ing BPD rate, could also be used as a clinical tool for wean-
ing the premature babies from CPAP and/or oxygen
therapy.
Most of the neonates with BPD have their pulmonary
disease defined clinically on the basis of oxygen depend-
ence at 36 weeks of postmestrual age (PMA). The valid-
ity of this definition is limited because the need for
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oxygen is determined not uniformly by individual clin-
ician [3] and there are no standard criteria for its use.
Moreover, the immaturity of respiratory control can in-
fluence oxygen use, medications and respiratory support
can influence the need for oxygen, last but not least the
use of oxygen at a specific time does not reflect a
chronic stage [4].
To minimize the influence of different strategies for
oxygen supplementation on the incidence of BPD, Walsh
et coll. Proposed a physiologic test to standardize the
need for oxygen at the time when BPD is diagnosed [2].
The use of this test, based on gradual oxygen weaning to
room air in selected infants receiving low amounts of
oxygen, made it clear that part of the reported variation
in BPD incidence among centres was due to differences
in clinical practice with respect to oxygen therapy [5].
BPD was originally described by Northway in a group of
preterm infants suffering from respiratory distress syn-
drome, who develop chronic respiratory failure and
radiographic pulmonary changes after prolonged mech-
anical ventilation and high inspiratory oxygen levels [6].
This severe form of BPD has been replaced in the last
years by a milder form that presents in the smaller in-
fants who frequently have only mild or no initial respira-
tory distress [7], described as “new BPD” [4].
The aim of our study was to verify if a modified
physiologic test can also be used as a clinical tool for
weaning the premature babies from respiratory support
and/or oxygen therapy. Several innovations character-
ized our study: 1) the test was performed also in the ba-
bies receiving CPAP, 2) even at 28 days of life (DOL) and
not only at 36 weeks PMA, 3) the newborn infants pass-
ing the test were left in room air; 4) transcutaneous gas
monitoring was added to the clinical observation, SpO2,
heart rate and respiratory rate monitoring.
Materials and methods
Study population
This prospective cohort study was carried out in our
neonatal intensive care unit (NICU) over a 2-year
period. Neonates with birth weight (BW) between 500 g
and 1250 g and with gestational age (GA) ≤ 32 weeks
were studied at 28 DOL and at 36 weeks PMA. Neonates
receiving at that times mechanical ventilation, or CPAP
and/or O2-therapy with fraction of inspired oxygen
(FiO2) > 0.30, were not performing the physiologic test.
Neonates on CPAP and/or on oxygen therapy with
FiO2 ≤ 0.30 at rest, with O2 saturation between 90 and
96%, underwent a timed stepwise reduction of CPAP
(for the babies managed with 6 cm H2O first reduction
to 4 cm H2O and then suspension of CPAP; for the
babies managed with 4 cm H2O direct suspension of
CPAP) and/or FiO2 to room air. Testing was done at
least 1 h after feeding while the infant was quiet and in
the supine position and it was performed into three
steps: baseline, challenge and post test. Baseline lasted
30min, in which the babies were observed at their initial
respiratory parameters. After it, challenge based on 2%
FiO2 reduction every 15 min till room-air was obtained.
If the babies reached room-air, they underwent the post
test based on a 60 min period of observation at FiO2
0.21. If the baby was on nasal CPAP, challenge consisted
on the suspension of CPAP. During the time test
neonates were monitored continuously with a
cardio-respiratory monitor (Hewlett Packard OmniCare),
a pulse oxymeter (Masimo®), a transcutaneous gas moni-
toring (Tina TCM4, Radiometer, Copenaghen) and ob-
served directly by an experienced neonatologist. During
the test, every 60 s the following parameters were re-
corded: transcutaneous partial pressure of CO2
(TcPCO2), transcutaneous partial pressure of O2
(TcPO2), heart rate, respiratory rate, SpO2.
Test failure was defined as the occurrence of any of
the following situations during any phase of the test:
SpO2 between 80 and 89% for 5 min with TcPO2 < 50
mmHg, or SpO2 < 80% for 1 min, or apnea (cessation of
breathing for > 20 s) and/or bradycardia (heart rate < 80
bpm for > 10 s). In these cases, the test was declared
failed and the infant returned to the prior oxygen level
immediately. The newborns passing the test were left in
room air and carefully observed by a neonatologist in
the following hours. The study protocol and consent
forms were approved by the Ethics Committee of the
Department of Pediatrics and the parents gave their
informed consent.
The incidence of major morbidities (IVH > 2°; proven
sepsis and patent ductus arteriosus surgically ligated)
before performing the test either at 28 days and 36 weeks
PMA was reported.
Statistical analysis
Continuous variables were described by mean and SD or
median and range and were compared using parametric
(one-way analysis of variance-ANOVA, Unpaired t test)
or non-parametric (Kruskal-Wallis, Mann-Whitney)
tests, as appropriate. Categorical variables were com-
pared using X2 test or a two-tailed Fisher’s exact test, as
appropriate. The statistical software used was GraphPad
PRISM Version 3.02. A p value < 0.05 was considered
statistically significant.
Results
During the study period 125 neonates with BW 500–
1250 g and with GA ≤ 32 weeks were admitted to our
NICU. Sixteen babies died before 28 days of life, while
61 babies were in room air and 25 were on mechanical
ventilation or CPAP with FiO2 > 0,30, so they did not
perform the test.
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We performed 33 tests on 31 preterm neonates, be-
cause two neonates did the test twice: they failed it at 28
DOL, but overcame it at 36 weeks PMA. All tested
infants received oxygen therapy for at least 28 days,
according to definition of new BPD.
Twenty-three neonates were examined at 28 days of
life: 6 overcame the test (Passed group), while 17 failed
it (Failed group). Table 1 shows patients characteristics,
major morbidities and respiratory support at 28 DOL.
Before the challenge, most infants of both groups were
on nasal CPAP of 4–6 cmH2O by nasal prongs. The
Failed group infants received significantly higher median
FiO2 levels respect to the Passed group ones (P = 0.03).
No differences were found in terms of respiratory rate
or heart rate between the two groups (data not shown).
The causes of failure are shown in Table 2. Six babies
passed the test (3 on CPAP of 6 cmH2O, 2 on CPAP of
4 cmH2O and 1 on O2-therapy) and were left into room
air: four did not need any respiratory support until dis-
charge; only two started again their ventilator support,
one because of bradycardia and hypoxia associated to a
not proven sepsis episode and one because of hypoxia
associated to pneumonia, both 48 h after passing the
test. Monitored SpO2 and TcPCO2 are reported in the
Fig. 1. Median SpO2 values were significantly higher in
the Passed group respect to the Failed group in all
phases of the test (P < 0.05). Median TcPCO2 values
were significantly higher in the neonates failing the test
respect to the Passed group at baseline, challenge and
post test (P < 0.05). Median [range] TcPO2 values were
always higher in the neonates passing the test respect to
those who failed it, but the only significant difference
was observed during the challenge phase: 69 [61–82]
mmHg and 56 [37–78] mmHg respectively (P < 0.05).
Only the neonates of the Passed group increased their
respiratory rate, rising from median [range] values of 52
[44–65] breaths/minute at the baseline, to 62 [46–84]
breaths per minute and 66 [46–82] breaths per minute
during the challenge and post test, respectively (One--
way ANOVA P = 0.12). The respiratory rate of the Failed
group remained instead unchanged during the phases of
the test: median [range] values of 51 [35–73] breaths/
minute at the baseline, 51 [33–86] breaths per minute
during the challenge and 52 [39–66] breaths/minute
during the post test. No significant respiratory rate dif-
ferences between Passed and Failed groups were found
during the three phases of the test.
At 36 weeks PMA 92 babies were in room air and 7
were on mechanical ventilation or CPAP with FiO2 >
0,30, so they did not perform the test. Ten neonates
were tested: 4 overcame the test (Passed group) and 6
failed it (Failed group). By applying the physiological def-
inition there was a reduction of BPD incidence from
15.6% (17/109) to 11.9% (13/109), and a reduction of se-
vere BPD from 7.3% (8/109) to 6.4% (7/109). Table 3
shows patients characteristics, major morbidities and re-
spiratory support at 36 weeks PMA. One out of 4 babies
(25%) of Passed Group was on nasal CPAP of 4 cmH2O
at the time of the test. The newborns of the Failed group
needed a significantly higher median FiO2 level respect
to the Passed group (P = 0.01). No differences were
found in terms of respiratory rate or hearth rate between
the two groups. The causes of failure of the test are
shown in Table 4. Only one baby of the 4 passing the
test (1 on CPAP and 3 on O2-therapy) was left without
respiratory support until discharge, whereas 3 started it
again: in one case after 3 days because of hypoxia associ-
ated with anaemia, in the other two cases after several
days because of hypoxia and bradycardia associated with
a proven sepsis. Figure 1 shows the values of monitored
Table 1 Patients characteristics, major morbidities and respiratory support at 28 DOL
All infants
(N 125)
Died infants (N
16)
Non tested infants
(room air) (N 61)
Non tested infants
(MV or FiO2 > 0.3) (N 25)
Failed Group
(N 17)
Passed Group
(N 6)
P1 P2
GA (wks) 28.0 ± 2.5 26.5 ± 1.5 29.8 ± 2.0 26.1 ± 1.4 26.5 ± 1.7 26.5 ± 1.8 < 0.0001 0.89
BW (g) 923 ± 234 752 ± 231 1061 ± 140 740 ± 227 856 ± 215 917 ± 187 < 0.0001 0.54
M/F 62/63 9/7 24/37 16/9 9/8 4/2 0.22 0.66
RDS 85 (68) 16 (100) 28 (46) 24 (96) 12 (70) 5 (83) < 0.0001 1
PDA 15 (12) 2 (12) 0 7 (28) 5 (29) 1 (17) 0.0007 1
IVH > 2° 14 (11) 3 (19) 2 (3) 7 (28) 3 (18) 0 0.01 0.54
Sepsis 37 (30) 6 (37) 13 (21) 11 (44) 5 (29) 2 (33) 0.28 1
Survival 104 (83) 0 61 (100) 21 (84) 16 (94) 6 (100) 0.01 1
Neonates on
CPAP
26 (21) 0 7 (28) 14 (82) 5 (83) < 0.0001 1
Baseline FiO2 0.21 [0.21–0.55] 0.21 [0.21–0.21] 0.30 [0.21–0.55] 0.25 [0.21–0.30] 0.21 [0.21–0.23] < 0.0001 0.03
Values are expressed as mean ± SD, median [range] or number (%)
P1: comparison between the groups; P2: comparison between the Failed and Passed groups
GA gestational age, BW birth weight, RDS respiratory distress syndrome, PDA patent ductus arteriosus surgically ligated, IVH intraventricular hemorrhage, FiO2
Fraction of inspired oxygen, MV mechanical ventilation, CPAP continuous positive airways pressure, MV mechanical ventilation
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SpO2 and TcPCO2 during the three different phases of
the test. Median SpO2 values were always higher in the
neonates passing the test respect to the Failed group and
the difference reached statistical significance only during
the challenge phase (p < 0.05). Median TcPCO2 values
were significantly higher in the Failed group as com-
pared to the Passed group only during the challenge
phase (P < 0.01). Median TcPO2 values were always
higher, but without statistical significance, in the neo-
nates passing the test respect to those who failed it. The
neonates of the Failed group decreased over time their
respiratory rate, from median [range] values of 64 [52–
73] breaths/minute at the baseline, to 55 [42–74] breaths
per minute and 44 [39–49] breaths per minute during
the challenge and post test, respectively (One-way
ANOVA P = 0.17), while the infants passing the test had
their respiratory rate unchanged during the three test
phases: median [range] values of 52 [40–57] breaths/mi-
nute at the baseline, 59 [49–65] breaths per minute dur-
ing the challenge and 53 [40–72] breaths per minute
during the post test. No significant respiratory rate dif-
ferences between Passed and Failed groups were found
during the three phases of the test.
Discussion
The physiologic test proposed by Walsh is a structured,
short period of oxygen saturation monitoring coupled
with gradual oxygen weaning to room air in selected in-
fants receiving low amounts of oxygen [2, 5]. In our
study we performed this test with four innovations. First
of all, we performed the test also at 28 DOL. Older stud-
ies defined BPD as treatment with supplemental oxygen
for longer than 28 to 30 days [8, 9], whereas more recent
studies have defined BPD as treatment with supplemen-
tal oxygen at 36 weeks PMA [10, 11]. Predictive values
of oxygen for ≥28 days, oxygen at 36 weeks PMA, and
the severity-based NIH consensus definition of BPD [12]
were recently evaluated in a large cohort of infants from
NICHD at 18 to 22months corrected age [13]. The 28
days of oxygen criteria is more sensitive in detecting
Table 2 Causes of failure of the test at 28 DOL
Cause of failure Baseline
(N 3)
Challenge
(N 10)
Post-test
(N 4)
Apnea 0 0 1
Bradycardia 1 0 1
SpO2 80–90% with TcPO2
< 50 mmHg for 5’
0 4 1
SpO2 < 80% for 1’ 2 6 1
Fig. 1 Recorded parameters at 28 days of life (DOL) and at 36 weeks post menstrual age (PMA) in the two groups of infants during the three
phases of the test. BL = Baseline; CH = Challenge; PT = Post-test; TcPCO2 = Transcutaneous partial pressure of CO2; ○ = Passed group; ● = Failed
group. Bar shows the median value for each group. Mann Whitney test was applied for comparisons between the groups
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post discharge respiratory complications, but has poor
specificity. The oxygen dependency at 36 weeks PMA is
more specific and more sensitive in predicting mental
and psychomotor developmental impairment [4, 13]. It
has to be taken into account that most of our patients
evaluated at 28 DOL suffered from RDS at birth and that
all needed a respiratory support and/or O2-therapy con-
tinuously during the first month of life. Oxygen, which
is vital to survival, can be highly damaging to neonatal
tissue which is known to be poorly equipped to
neutralize toxic derivatives. Recently a marker of oxida-
tive stress in preterm newborns was found [14]. Preterm
infants are often exposed to high oxygen concentrations,
infections or inflammation; they have reduced antioxi-
dant defense and high free iron levels which enhance
toxic radical generation [15]. Using lung protective strat-
egies or by performing tests like ours, coupled with
gradual oxygen weaning to room air in selected infants
receiving low amounts of oxygen, could be very useful to
prevent oxidative induced lung injury in preterm infants.
Second, the test was performed also in neonates receiv-
ing CPAP when their FiO2 was ≤30%. It was very inter-
esting that 5 of the six neonates that overcame the test
at 28 DOL were on CPAP, and only 2 started again their
respiratory support in the following days, while at 36
weeks PMA of the 4 neonates passing the test only one
was on CPAP and he started again his respiratory sup-
port in the following days. The possibility of suspending
both O2-therapy and nasal-CPAP, represents an undeni-
able gain not only for newborn’s welfare, but also for
enhancing the sound of material and human resources.
Moreover weaning from CPAP at 36 weeks PMA could
impact the rate of severe BPD (“new BPD”). In our
centre the proportion of infants requiring mechanical
ventilation is very low, so by applying the physiological
definition there was a reduction of severe BPD from
7.3% (8/109) to 6.4% (7/109).
Third, we introduced the transcutaneous gas monitoring.
In particular, TcPCO2 could be a good criterion for failure’s
prediction, being always significantly higher in the Failed
group. In infants with BPD, hypercapnia reflects the pres-
ence of a more severe lung disease and may be the result of
a combination of ventilation/perfusion (V/Q) imbalance,
hypoventilation, and diaphragmatic fatigue [16–18]. There
is also evidence that infants with BPD have an impaired re-
spiratory response to pCO2 [19] as showed by respiratory
rate behaviour. In addition the presence of hypercapnia
suggests reduced ventilator reserve, with an increased risk
of ventilator failure in the presence of added mechanical or
metabolic stress [17].
Last but not least, we intended to use the test also to
guide clinical decision about an individual’s patient care,
so we modified the length of each phase of the test. The
baseline period, which lasted 15min in Walsh’s study was
lengthened to 30min. During the challenge phase, each
step of reduction lasted 15min instead of the 5 decided by
Walsh, to better evaluate the effects of each reduction on
baby’s condition and saturation. Moreover we performed a
longer observation in room air: 60min in our study vs 30
min in Walsh’s experience. Someone may argue that in
Table 3 Patients characteristics, major morbidities and respiratory support at 36 weeks PMA
Non tested infants (room air)
(N 92)
Non tested infants (MV or FiO2 > 0.3)
(N 7)
Failed Group
(N 6)
Passed Group
(N 4)
P1 P2
GA (wks) 28.7 ± 2.4 25.9 ± 2.0 25.5 ± 1.6 26.0 ± 0.8 < 0.0001 0.36
BW (g) 995 ± 191 667 ± 274 673 ± 141 752 ± 245 < 0.0001 0.53
M/F 41/51 5/2 4/2 3/1 0.30 1
RDS 53 (58) 6 (86) 6 (100) 4 (100) 0.03 0.40
PDA 6 (6) 3 (43) 2 (33) 2 (50) 0.0007 1
IVH > 2° 8 (9) 2 (28) 0 (0) 1 (25) 0.20 0.40
Sepsis 29 (31) 5 (71) 4 (67) 2 (50) 0.06 0.50
Survival 91 (99) 4 (57) 6 (100) 3 (75) < 0.0001 0.40
Neonates on CPAP 0 1 (14) 0 1 (25) 0.0002 1
Baseline FiO2 0.21 [0.21–0.21] 0.30 [0.21–0.50] 0.25 [0.23–0.27] 0.23 [0.21–0.23] < 0.0001 0.01
Values are expressed as mean ± SD, median [range] or number (%)
P1: comparison between the groups; P2: comparison between the Failed and Passed groups
GA gestational age, BW birth weight, RDS respiratory distress syndrome, PDA patent ductus arteriosus surgically ligated, IVH intraventricular hemorrhage, FiO2
Fraction of inspired oxygen, MV mechanical ventilation
Table 4 Causes of failure of the test at 36 weeks PMA
Adverse event Baseline
(N 0)
Challenge
(N 4)
Post-test
(N 2)
Apnea 0 0 0
Bradycardia 0 0 0
SpO2 80–90% with TcPO2
< 50 mmHg for > 5’
0 2 1
SpO2 < 80% for 1′ 0 2 1
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this way the test required more than 2 h to be performed,
loosing its feasibility. Nevertheless, the median length of
test in failed group was 53min [9–104] and 50min [40–
135], respectively at 28 DOL and at 36 weeks PMA, dem-
onstrating the need of a longer duration of the physiologic
challenge. It is important to note that the neonates passing
the test but requiring respiratory support and/or O2-ther-
apy in the following days were all affected by
non-respiratory (mainly infective) diseases. This under-
lines the utility of our test as a clinical tool for weaning
preterm newborns from their respiratory support.
In our study, the Passed and Failed groups were simi-
lar with respect to gestational age, birth weight and
major morbidities. The infants who failed the test had
lower median SpO2 values compared to the babies who
have passed the test, while receiving a significantly
greater FiO2. These data underline the alteration of V/Q
relationship, one of the characteristics of BPD; in fact
non-uniform damage to the airways and distal lungs
results in variable time constants for different areas of
the lungs, the inspired gas might be distributed to poorly
perfused lungs, and worsening ventilation-perfusion
matching [20]. Of the other monitored parameters, me-
dian TcPCO2 values were always higher in the Failed
group during the three phases of the test. It is important
to note that at 28 DOL 19/23 studied infants (83%) were
on nasal CPAP. During the challenge and post test
phases, it is conceivable that infants deprived of any re-
spiratory support, should provide themselves to maintain
a functional residual capacity, which can be imple-
mented by increasing the respiratory rate. While the
neonates of Passed group increased their respiratory
rate, infants of Failed group maintained a respiratory
rate essentially unchanged during the three phases of the
test, despite the significantly higher values of TcPCO2. It
is possible that the babies of the Failed group had a ten-
dency to breathe with less efficiency respect to the
babies of Passed group, for a combined effect of more
severe lung injury (as shown by their higher FiO2 re-
quirement at baseline), immaturity of central inspiratory
drive (as shown by a lower respiratory rate during the
test) and impaired respiratory muscle strength.
Kovesi et al. showed that pCO2 values are related
to an increased incidence of adverse events, defined
as death, need for respiratory assistance and/or
tracheotomy and pulmonary hypertension [21]. As
demonstrated by Kaempf et al. in a multicenter study,
pCO2 and SpO2 values appears to be reasonable good
markers of lung injury [22]: the authors studied 220
babies at 36 weeks PMA, subjecting them to a chal-
lenge of 1 h to FiO2 0.21. Median pCO2 values were
significantly higher in infants with BPD compared to
controls: 54 mmHg vs 45 mmHg, respectively, consist-
ent with the results of our study.
Conclusion
The test has proven to be safe and feasible, in fact neo-
nates were monitored by a clinician in each step of the
test, while direct observation is only intermittent in rou-
tine clinical practice during FiO2 weaning. We want also
to underline the utility of a follow up of the neonates pass-
ing the test in order to validate it for clinical management.
In contrast to the method of Walsh, in our study infants
were left in room air if the challenge was passed with the
intention of using the test as a clinical tool for weaning.
We have shown that some infants did not need the re-
spiratory support they were being given at that time. In
our experience half of the infants who passed the test,
later required respiratory support, although this can cer-
tainly not be attributed to respiratory failure.
We hope that infants kept on oxygen and/or respira-
tory support could be removed sooner by using our test.
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